A new study has shown that higher ratings of mystical-type experiences induced by psychedelics were associated with greater increases in the attribution of consciousness.
The trial MDMA-assisted therapy for post-traumatic stress disorder (PTSD) has advanced to the next implementation phase.
Follow-up data from a Phase III clinical trial shows that MDMA therapy could hold promise for millions suffering from the condition.
Cybin Inc.
The Psychedelic Society’s event Action for change: Drug Policy Symposium will be providing an opportunity for audiences to learn from experts in the UK.
Psyched Wellness and the National Research Council of Canada (NRC) have announced preliminary data from studies of the neuroprotective and anti-inflammatory properties of AME-1.
Leading UK psychedelics company Compass Pathways is entering into a pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate...
Data from Wesana Health indicates that administration of imipramine given three weeks following a psilocybin loading dose provided a 39 per cent improvement in depressive behaviours...
New research has suggested that sub-anaesthetic doses of ketamine could be beneficial for conditions such as post-traumatic stress disorder (PTSD), anxiety, addiction and eating disorders.
A systemic review of evidence has shown a lack of scientific research describing the interactions between widely used psychiatric medications and psychedelics like psilocybin and MDMA.
Results from a systematic review have led to the conclusion that psilocybin is safe to administer in clinical settings, and that there is a need to...
Researchers have said psychedelic-assisted psychotherapy may hold promise for both improving health and saving costs, but that the current therapeutic approach is poorly targeted.
